Reducing the risk of perinatal HIV‐1 transmission with zidovudine: results and implications of AIDS Clinical Trials Group protocol 076

Abstract

This paper reviews the rationale for the AIDS Clinical Trials Group (ACTG) protocol 076 design, the study results and the implications of these results, including discussion of the US Public Health Service Task Force recommendations on the use of zidovudine to reduce perinatal transmission and for prenatal human immunodeficiency virus (HIV) counseling and testing.